Novo Nordisk (
NVO) is showing classic strength — bouncing off the cloud, reclaiming structure, and flashing early signs of momentum rotation. This is how you catch continuation trades without chasing.
📊 Technical Breakdown
Ichimoku: Price reclaimed the top of the cloud and is now building above it. Kijun and Tenkan are aligned. This is the first real bullish structure since the March breakdown.
MACD: Histogram curling upward. We’re not fully bullish yet, but the pressure is shifting back to buyers.
R1 Pivot ($81.31) is the first big test. A clean break above that opens the path toward R2 and beyond.
🎯 Trade Specs
Entry: $71.58
Target: $93.33 (+30.44%)
Stop: $67.00 (–6.42%)
Risk/Reward: 4.74 — elite-level skew for a high-quality name
NVO) is showing classic strength — bouncing off the cloud, reclaiming structure, and flashing early signs of momentum rotation. This is how you catch continuation trades without chasing.📊 Technical Breakdown
Ichimoku: Price reclaimed the top of the cloud and is now building above it. Kijun and Tenkan are aligned. This is the first real bullish structure since the March breakdown.
MACD: Histogram curling upward. We’re not fully bullish yet, but the pressure is shifting back to buyers.
R1 Pivot ($81.31) is the first big test. A clean break above that opens the path toward R2 and beyond.
🎯 Trade Specs
Entry: $71.58
Target: $93.33 (+30.44%)
Stop: $67.00 (–6.42%)
Risk/Reward: 4.74 — elite-level skew for a high-quality name
Dagangan ditutup secara manual
2% loss. closing this out
If you found my trades helpful, please consider sending a tip in BTC to: bc1qr35mrh82hykpy9v6znpsyuew85x84ezjyrrf6m
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
If you found my trades helpful, please consider sending a tip in BTC to: bc1qr35mrh82hykpy9v6znpsyuew85x84ezjyrrf6m
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.